Erastin: Precision Ferroptosis Inducer for Cancer and Oxidative Stress Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, a regulated, iron-dependent form of cell death distinct from apoptosis. It selectively kills tumor cells with RAS or BRAF mutations by elevating reactive oxygen species (ROS) and inhibiting cystine uptake (Yang et al. 2021, DOI). The compound modulates the voltage-dependent anion channel (VDAC) and the cystine/glutamate antiporter system Xc⁻, disrupting redox balance. Erastin is widely used in research on ferroptosis, oxidative stress, and cancer therapy resistance, with robust evidence in both in vitro and in vivo models (Wang et al. 2024, DOI). APExBIO provides Erastin (SKU B1524) for reproducible cellular assays, with stable formulation and detailed protocols (product page).

Biological Rationale

Ferroptosis is a genetically and biochemically distinct mode of regulated cell death characterized by iron-dependent lipid peroxidation (Wang et al. 2023, DOI). Unlike apoptosis, ferroptosis does not involve caspase activation but is marked by mitochondrial shrinkage, loss of cristae, and dense membrane structure (Yang et al. 2021, DOI). This pathway is relevant to tumor cell vulnerability, neurodegeneration, and metabolic disease. Tumor cells with oncogenic RAS or BRAF mutations are hypersensitive to ferroptosis due to altered redox metabolism. Erastin exploits this vulnerability, making it a strategic tool for dissecting cell death pathways and developing therapies that overcome resistance to traditional apoptosis-inducing drugs. Ferroptosis is also implicated in cognitive decline and diabetes complications, highlighting its translational significance (Wang et al. 2024, DOI).

Mechanism of Action of Erastin

Erastin induces ferroptosis through two principal mechanisms:

• VDAC Modulation: Erastin binds the voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane, increasing mitochondrial permeability and promoting ROS accumulation (APExBIO).
• System Xc⁻ Inhibition: Erastin inhibits the cystine/glutamate antiporter system Xc⁻ (SLC7A11/SLC3A2), blocking cystine uptake and reducing intracellular glutathione (GSH) synthesis (Wang et al. 2024, DOI).

These actions drive glutathione depletion, inactivate glutathione peroxidase 4 (GPX4), and promote lethal lipid peroxidation. The result is selective, iron-dependent, caspase-independent cell death. Erastin's effects are potentiated in cells with RAS/RAF pathway activation, linking its efficacy to oncogenic signaling and metabolic reprogramming. This mechanism is discussed in detail in Erastin: Mechanistic Insights and Emerging Frontiers in Ferroptosis Research, which focuses on molecular underpinnings; the present article extends this by highlighting translational and workflow guidance.

Evidence & Benchmarks

• Erastin reliably induces ferroptosis in HT-1080 fibrosarcoma cells at 10 μM for 24 hours, resulting in increased mitochondrial density and loss of cristae (Yang et al. 2021, DOI).
• In STZ-induced T2DM mouse models, Erastin administration abolishes the neuroprotective effects of artemisinin, confirming its role as a ferroptosis trigger in vivo (Wang et al. 2024, DOI).
• Erastin treatment elevates hippocampal ROS, malondialdehyde (MDA), and Fe²⁺ levels while depleting GSH and GPX4 proteins (Wang et al. 2024, Table 2, DOI).
• Selective cytotoxicity is observed in RAS- or BRAF-mutant tumor cells versus wild-type controls, supporting its use in targeted cancer research (internal guide).
• APExBIO's Erastin (B1524) is formulated as a solid, with molecular weight 547.04 g/mol, and achieves ≥10.92 mg/mL solubility in DMSO with mild warming (product page).

Applications, Limits & Misconceptions

Erastin is used for:

• Mechanistic dissection of ferroptosis and redox regulation in cancer, neurodegeneration, and metabolic disease research.
• High-throughput screens for ferroptosis modulators or sensitizers in RAS/BRAF-mutant tumor models.
• Oxidative stress pathway assays, especially for evaluating GPX4, GSH, and ROS dynamics.
• Preclinical evaluation of ferroptosis-targeting therapies in combination with other pathway inhibitors.

Recent reviews such as Erastin and the Translational Frontier map emerging translational applications. This article clarifies current experimental parameters and benchmarks for reliable use.

Common Pitfalls or Misconceptions

• Erastin is not effective in cells lacking iron-dependent metabolism; iron chelators can block its effects (Wang et al. 2024, DOI).
• It does not induce apoptosis; Erastin acts via caspase-independent pathways.
• Long-term storage of Erastin in solution leads to loss of potency; always prepare fresh DMSO stocks (APExBIO).
• Off-target effects may occur at concentrations >20 μM; optimal activity is at 10 μM for 24 h in most cell models.
• Water or ethanol are unsuitable solvents due to Erastin's low solubility; use DMSO with gentle warming.

Workflow Integration & Parameters

For reproducible results, dissolve Erastin (SKU B1524) at ≥10.92 mg/mL in DMSO with gentle warming. Use freshly prepared solutions, as stability is limited in solution form. Store solid Erastin at -20°C. Typical in vitro experiments treat HT-1080 or engineered RAS/BRAF-mutant tumor cells with 10 μM Erastin for 24 hours. Assess endpoints using ROS, MDA, GSH, and Fe²⁺ quantification, plus Western blot for GPX4 and Nrf2. For in vivo studies, Erastin is used as a reference ferroptosis inducer to validate pathway dependence in models such as STZ-induced diabetic mice (Wang et al. 2024, DOI). For expanded troubleshooting and advanced applications, see Erastin: A Precision Ferroptosis Inducer for Cancer Biology, which provides workflow extensions beyond the present summary.

Conclusion & Outlook

Erastin is a validated, selective ferroptosis inducer with robust experimental benchmarks and mechanistic clarity. It remains a cornerstone for research on oxidative stress and RAS/RAF-driven cancers. By leveraging APExBIO's high-purity Erastin (B1524), researchers can dissect ferroptosis pathways and evaluate new therapeutic strategies with confidence. Ongoing work continues to refine dosing, combinatorial regimens, and in vivo modeling, supporting the translation of ferroptosis modulation into clinical oncology and beyond. For further mechanistic insight and strategic integration, see Erastin and the Ferroptosis Frontier: Strategic Integration, which explores competitive context and clinical translation—this article provides updated, practical workflow guidance for immediate research use.